Stockreport

Third Harmonic Bio Announces Third Quarter 2024 Financial Results

Third Harmonic Bio, Inc.  (THRD) 
PDF THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $296.1 million as [Read more]